{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:19:47Z","timestamp":1783181987614,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1I1A20474750"],"award-info":[{"award-number":["NRF-2021R1I1A20474750"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.115043","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:32:29Z","timestamp":1727469149000},"page":"115043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation"],"prefix":"10.1016","volume":"212","author":[{"given":"Hanseung","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woohyeon","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Chan","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Kyu","family":"Chie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chai Hong","family":"Rim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2024.115043_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115043_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","article-title":"Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis","volume":"109","author":"Rim","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2024.115043_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","article-title":"Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study","volume":"168","author":"Willmann","year":"2022","journal-title":"Radio Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115043_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","article-title":"Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 Trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115043_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijrobp.2022.06.067","article-title":"Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO\/EORTC Nomenclature","volume":"114","author":"Nevens","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2024.115043_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4143\/crt.2023.876","article-title":"Radiation oncologists' perspectives on oligometastatic disease: a Korean Survey study","volume":"56","author":"Rim","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115043_bib8","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","author":"Wang","year":"2022","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"10422","key":"10.1016\/j.ejca.2024.115043_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2024.115043_bib11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115043_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4143\/crt.2022.329","article-title":"Role of local treatment for oligometastasis: a comparability-based meta-analysis","volume":"54","author":"Rim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115043_bib13","author":"Peterson","year":"2011","journal-title":"Newctle-Ott Scale (NOS) Assess Qual nonrandomised Stud meta-Anal"},{"key":"10.1016\/j.ejca.2024.115043_bib14","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Ch 24.6: Synthesis of results from non-randomized studies","author":"Higgins","year":"2019"},{"issue":"9","key":"10.1016\/j.ejca.2024.115043_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib16","first-page":"1","article-title":"Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography\/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis","author":"Song","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115043_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijrobp.2014.07.012","article-title":"Propensity score\u2013matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy","volume":"90","author":"Sheu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"10.1016\/j.ejca.2024.115043_bib18","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2217\/fon-2018-0923","article-title":"Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer","volume":"15","author":"Shang","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.09.021","article-title":"Local ablative treatment for synchronous single organ oligometastatic lung cancer\u2014A propensity score analysis of 180 patients","volume":"125","author":"Frost","year":"2018","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.115043_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jso.21750","article-title":"Prognostic impact of local treatment against postoperative oligometastases in non\u2010small cell lung cancer","volume":"102","author":"Yano","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fonc.2020.00470","article-title":"Oligorecurrence non\u2013small cell lung cancer after failure of first-line chemotherapy: computed tomography\u2013guided 125I seed implantation vs. second-line chemotherapy","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00432-019-03043-6","article-title":"Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment","volume":"146","author":"Ni","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib23","first-page":"8209","article-title":"Combination of brachytherapy with iodine-125 seeds and systemic chemotherapy versus systemic chemotherapy alone for synchronous extracranial oligometastatic non-small cell lung cancer","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"12","key":"10.1016\/j.ejca.2024.115043_bib24","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1111\/cas.14605","article-title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non\u2010small cell lung cancer","volume":"111","author":"Kagawa","year":"2020","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib25","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2024.115043_bib26","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2147\/OTT.S300267","article-title":"Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients","volume":"14","author":"Hsu","year":"2021","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib27","first-page":"36","article-title":"Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis","volume":"15","author":"He","year":"2017","journal-title":"World J Surg Urol"},{"issue":"2","key":"10.1016\/j.ejca.2024.115043_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.lungcan.2014.06.001","article-title":"Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival","volume":"85","author":"Gray","year":"2014","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/curroncol28010059","article-title":"Survival impact of aggressive treatment and PD-L1 expression in oligometastatic NSCLC","volume":"28","author":"Gauvin","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib30","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2020.07.011","article-title":"Management of non\u2013small-cell lung cancer patients initially diagnosed with 1 to 3 synchronous brain-only metastases: a retrospective study","volume":"22","author":"Chen","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.115043_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00540","article-title":"Benchmarking outcomes for molecularly characterized synchronous oligometastatic non\u2013small-cell lung cancer reveals EGFR mutations to be associated with longer overall survival","author":"De","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cllc.2023.09.002","article-title":"Patterns of failure in metastatic NSCLC treated with first line pembrolizumab and use of local therapy in patients with oligoprogression","volume":"25","author":"Friedes","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2024.115043_bib33","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.2147\/CMAR.S345871","article-title":"Efficacy and safety of local radiotherapy to all oligometastatic sites in elderly patients with metachronous oligometastatic cancers after initial treatment for the primary tumor","author":"Hu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2024.115043_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156387","article-title":"Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC","volume":"15","author":"Xuzhang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1259880","article-title":"The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases","volume":"13","author":"Zhou","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.115043_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.26312","article-title":"Evaluation of definitive stereotactic body radiotherapy and outcomes in adults with extracranial oligometastasis","volume":"3","author":"Poon","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ejca.2024.115043_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2018.04.022","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2024.115043_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6449-8","article-title":"Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer","volume":"19","author":"Kissel","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.115043_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2379-x","article-title":"Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer","volume":"16","author":"Fleckenstein","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2024.115043_bib40","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.21873\/anticanres.14609","article-title":"Prognostic significance of oligometastatic disease classification by the ESTRO\/EORTC of cancer for patients with lung cancer treated with definitive radical radiotherapy","volume":"40","author":"Chen","year":"2020","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.115043_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","article-title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature","volume":"82","author":"Ashworth","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.115043_bib42","series-title":"AJCC cancer staging manual","article-title":"editors","author":"Edge","year":"2010"},{"issue":"2","key":"10.1016\/j.ejca.2024.115043_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4143\/crt.2023.876","article-title":"Radiation oncologists\u2019 perspectives on oligometastatic disease: a Korean survey study","volume":"56","author":"Rim","year":"2024","journal-title":"Cancer Res Treat: J Korean Cancer Assoc"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115043_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41698-020-00141-4","article-title":"Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review","volume":"5","author":"Rim","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115043_bib46","article-title":"Stepwise-hierarchical pooled analysis for synergistic interpretation of meta-analyses involving randomized and observational studies: methodology development","volume":"23","author":"Shin","year":"2021","journal-title":"J Med Internet Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:30:39Z","timestamp":1737667839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924010098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"alternative-id":["S0959804924010098"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115043","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115043"}}